Literature DB >> 1706450

Hyperdynamic circulation in cirrhosis: a role for nitric oxide?

P Vallance1, S Moncada.   

Abstract

Hypotension, low systemic vascular resistance, and a reduced sensitivity to vasoconstrictors are features of cirrhosis. These cardiovascular changes might be the result of increased synthesis of a vasodilator. Nitric oxide (NO), a potent vasodilator, is synthesised in and released from peripheral blood-vessels in man. Studies in animals indicate that bacterial endotoxin and cytokines induce NO synthase expression in vessel walls, with sustained NO release and consequent hypotension. Endotoxaemia is a common feature of cirrhosis; persistent induction of NO synthase may account for the associated haemodynamic changes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706450     DOI: 10.1016/0140-6736(91)91384-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  96 in total

1.  Parathyroid hormone-related protein in liver cirrhosis.

Authors:  E Fabrega; M Rivero; F Pons-Romero; M T García-Unzueta; J A Amado
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

2.  Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility.

Authors:  R Wiest; S Das; G Cadelina; G Garcia-Tsao; S Milstien; R J Groszmann
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 3.  The hepatorenal syndrome.

Authors:  L Dagher; K Moore
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

Review 4.  Nitric oxide in patients with cirrhosis and bacterial infections.

Authors:  José Such; Rubén Francés; Miguel Pérez-Mateo
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

5.  Physiopathology of splanchnic vasodilation in portal hypertension.

Authors:  María Martell; Mar Coll; Nahia Ezkurdia; Imma Raurell; Joan Genescà
Journal:  World J Hepatol       Date:  2010-06-27

6.  Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites.

Authors:  Georgios Kalambokis; Michalis Economou; Andreas Fotopoulos; Jihad Al Bokharhii; Pappas Christos; Kosta Paraskevi; Papadimitriou Konstantinos; Afroditi Katsaraki; Epameinondas V Tsianos
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

7.  Could serum nitrate and nitrite levels possibly predict hepatorenal syndrome in hepatitis C virus-related liver cirrhosis?

Authors:  Waheed Abdelmonsef Mahmoud; Nadia Abdelaaty Abdelkader; Amal Mansor
Journal:  Indian J Gastroenterol       Date:  2013-11-29

8.  Analysis of impaired exercise capacity in patients with cirrhosis.

Authors:  S K Epstein; R L Ciubotaru; M D Zilberberg; L M Kaplan; C Jacoby; R Freeman; M M Kaplan
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

9.  Glucagon, stress, and portal hypertension. Plasma glucagon levels and portal hypertension in relation to anesthesia and surgical stress.

Authors:  T J Johnson; E M Quigley; T E Adrian; G Jin; L F Rikkers
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

10.  Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites.

Authors:  M Sàbat; C Guarner; G Soriano; O Bulbena; M T Novella; J Ortiz; E Ricart; C Villanueva; J Rosello; J Rodríguez; J Balanzó
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.